Myriad Genetics’ continued investment in molecular residual disease (MRD) testing drives new patents granted October 7, 2025 Myriad Genetics is strengthening its position in the high-growth molecular residual disease (MRD) testing market with newly granted patents that expand protect... Continue Reading